TP53 and cancer: Our findings indicate that several clinicopathological factors, such as sample types, individual cancer stage, patient race, gender, weight, age, histologic subtype, nodal metastasis status, and TP53 mutant status, have an impact on FTO expression in colon cancer (Fig. 2A).